As of 3:52pm ET
| -0.029 / -8.06%|
Other Consumer Services
TapImmune, Inc. is focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease. The company combines a set of proprietary technologies to improve the ability of the cellular immune system to destroy diseased cells. It also provides treatment for other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system. TapImmune was founded in 1991 and is headquartered in Seattle, Washington.
|Glynn Wilson||Chairman, CEO, CFO, Secretary & CAO|
|Denis D. Corin||President & Director|
|Robert Z. Florkiewicz||Senior Director-Molecular Biology & Head-Research|
|Mark Reddish||Director & Vice President-Development|